Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.52 |
| ▸ | ABCG2 | Q9UNQ0 | 7/20 | 0.52 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.52 |
| ▸ | LTK | P29376 | 2/20 | 0.52 |
| ▸ | MAPK8 | P45983 | 2/20 | 0.52 |
| ▸ | LIMK1 | P53667 | 2/20 | 0.52 |
| ▸ | ACVR1 | Q04771 | 2/20 | 0.52 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.52 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.52 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.52 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.52 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.52 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.52 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.52 |
| ▸ | ABL1 | P00519 | 1/20 | 0.52 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.52 |
| ▸ | PIM1 | P11309 | 1/20 | 0.52 |
| ▸ | PRKACA | P17612 | 1/20 | 0.52 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.52 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16151185 | 0.81 | EGFR (0.54) | EGFRABCG2MAP4K4LTKMAPK8 | |
| SCHEMBL16156188 | 0.79 | EGFR (0.59) | EGFRABCG2PDGFRAKDRCLK1 | |
| SCHEMBL8920 | 0.70 | EGFR (1.00) | EGFRABCG2MAP4K4LTKMAPK8 | |
| SCHEMBL29941271 | 0.70 | EGFR (1.00) | EGFRABCG2MAP4K4LTKMAPK8 | |
| SCHEMBL8976752 | 0.70 | EGFR (0.78) | EGFRABCG2MAP4K4LTKMAPK8 | |
| SCHEMBL12131851 | 0.70 | GRM5 (0.43) | NPC1RAB9ASMN1; SMN2MAPK1GRM5 | |
| SCHEMBL6823372 | 0.70 | EGFR (0.77) | EGFRABCG2MAP4K4LTKMAPK8 | |
| SCHEMBL13138811 | 0.69 | GRM5 (0.44) | EGFRABCG2TYRO3KDRHTT | |
| Hydrochloric Acid SCHEMBL29394578 | 0.69 | EGFR (0.96) | EGFRABCG2MAP4K4LTKMAPK8 | |
| Hydrochloric Acid SCHEMBL20856873 | 0.69 | EGFR (0.96) | EGFRABCG2MAP4K4LTKMAPK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021099-A1 | Cancer Treatment Targeted to Tumor Adaptive Responses to Protein Synthesis Stress | UNIV CALIFORNIA (US) | 2026-01-22 | — | — | US | disclosed |
| US-12427148-B2 | Cancer treatment targeted to tumor adaptive responses to protein synthesis stress | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-09-30 | — | — | US | disclosed |
| US-20220152035-A1 | Cancer Treatment Targeted to Tumor Adaptive Responses to Protein Synthesis Stress | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-05-19 | — | — | US | disclosed |
| US-11253522-B2 | Cancer treatment targeted to tumor adaptive responses to protein synthesis stress | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-02-22 | — | — | US | disclosed |
| US-20190328740-A1 | Cancer Treatment Targeted to Tumor Adaptive Responses to Protein Synthesis Stress | UNITED STATES GOVERNMENT | 2019-10-31 | — | — | US | disclosed |
| US-9688662-B2 | N-(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-4-quinazolinamine and N-(2,3-dihydro-1H-indol-5-yl)-4-quinazolinamine derivatives as perk inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-27 | — | — | US | disclosed |
| US-9688662-B2 | N-(2,3-dihydro-1H-pyrrolo[2,3-b]pyridin-5-yl)-4-quinazolinamine and N-(2,3-dihydro-1H-indol-5-yl)-4-quinazolinamine derivatives as perk inhibitors | JANSSEN PHARMACEUTICA NV (BE) | 2017-06-27 | — | — | US | disclosed |
| EP-2989091-B1 | NOVEL N-(2,3-DIHYDRO-1H-PYRROLO[2,3-B]PYRIDIN-5-YL)-4- QUINAZOLINAMINE AND N-(2,3-DIHYDRO-1H-INDOL-5-YL)-4- QUINAZOLINAMINE DERIVATIVES AS PERK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-10 | — | — | EP | disclosed |
| EP-2989091-B1 | NOVEL N-(2,3-DIHYDRO-1H-PYRROLO[2,3-B]PYRIDIN-5-YL)-4- QUINAZOLINAMINE AND N-(2,3-DIHYDRO-1H-INDOL-5-YL)-4- QUINAZOLINAMINE DERIVATIVES AS PERK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-05-10 | — | — | EP | disclosed |
| EP-2989091-A1 | NOVEL N-(2,3-DIHYDRO-1H-PYRROLO[2,3-B]JPYRIDIN-5-YL)-4- QUINAZOLINAMINE AND N-(2,3-DIHYDRO-1H-INDOL-5-YL)-4- QUINAZOLINAMINE DERIVATIVES AS PERK INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2016-03-02 | — | — | EP | disclosed |
| EP-2989091-A1 | NOVEL N-(2,3-DIHYDRO-1H-PYRROLO[2,3-B]JPYRIDIN-5-YL)-4- QUINAZOLINAMINE AND N-(2,3-DIHYDRO-1H-INDOL-5-YL)-4- QUINAZOLINAMINE DERIVATIVES AS PERK INHIBITORS | Janssen Pharmaceutica, N.V. (BE) | 2016-03-02 | — | — | EP | disclosed |
| US-20160039798-A1 | NOVEL N-(2,3-DIHYDRO-1H-PYRROLO[2,3-b]PYRIDIN-5-YL)-4-QUINAZOLINAMINE AND N-(2,3-DIHYDRO-1H-INDOL-5-YL)-4-QUINAZOLINAMINE DERIVATIVES AS PERK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-11 | — | — | US | disclosed |
| US-20160039798-A1 | NOVEL N-(2,3-DIHYDRO-1H-PYRROLO[2,3-b]PYRIDIN-5-YL)-4-QUINAZOLINAMINE AND N-(2,3-DIHYDRO-1H-INDOL-5-YL)-4-QUINAZOLINAMINE DERIVATIVES AS PERK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2016-02-11 | — | — | US | disclosed |
| CN-105102450-A | Novel N- (2, 3-dihydro-1H-pyrrolo [2, 3-b ] pyridin-5-yl) -4-quinazolinamine and N- (2, 3-dihydro-1H-indol-5-yl) -4-quinazolinamine derivatives as PERK inhibitors | JANSSEN PHARMACEUTICA NV | 2015-11-25 | — | — | CN | disclosed |
| WO-2014161808-A1 | NOVEL N-(2,3-DIHYDRO-1H-PYRROLO[2,3-B]JPYRIDIN-5-YL)-4- QUINAZOLINAMINE AND N-(2,3-DIHYDRO-1H-INDOL-5-YL)-4- QUINAZOLINAMINE DERIVATIVES AS PERK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-09 | — | — | WO | disclosed |
| WO-2014161808-A1 | NOVEL N-(2,3-DIHYDRO-1H-PYRROLO[2,3-B]JPYRIDIN-5-YL)-4- QUINAZOLINAMINE AND N-(2,3-DIHYDRO-1H-INDOL-5-YL)-4- QUINAZOLINAMINE DERIVATIVES AS PERK INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160039798-A1 | NOVEL N-(2,3-DIHYDRO-1H-PYRROLO[2,3-b]PYRIDIN-5-YL)-4-QUINAZOLINAMINE AND N-(2,3-DIHYDRO-1H-INDOL-5-YL)-4-QUINAZOLINAMINE DERIVATIVES AS PERK INHIBITORS | MAPK1, RPS6KA1, RPS6KA5 | EGFR 584/4885ABCG2 1879/4885MAP4K4 42/4885 |
| US-20260021099-A1 | Cancer Treatment Targeted to Tumor Adaptive Responses to Protein Synthesis Stress | MYC, MYCBP, EIF4EBP1 | EGFR 82/4885ABCG2 2682/4885MAP4K4 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.